Assessment of Disease Severity and Quality of Life in Patients with Atopic Dermatitis from South Korea
- Authors
- Son, Sang Wook; Lee, Ji Hyun; Ahn, Jiyoung; Chang, Sung Eun; Choi, Eung Ho; Han, Tae Young; Jang, Yong Hyun; Kim, Hye One; Kim, Moon-Bum; Kim, You Chan; Ko, Hyun Chang; Ko, Joo Yeon; Lee, Sang Eun; Lee, Yang Won; Lew, Bark-Lynn; Na, Chan Ho; Park, Chang Ook; Park, Chun Wook; Park, Kui Young; Park, Kun; Park, Young Lip; Roh, Joo Young; Seo, Young-Joon; Shin, Min Kyung; Lee, Sujin; Cho, Sang Hyun
- Issue Date
- Dec-2022
- Publisher
- 대한피부과학회
- Keywords
- Anxiety; Atopic dermatitis; Depression; Quality of life
- Citation
- Annals of Dermatology, v.34, no.6, pp 419 - 430
- Pages
- 12
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- Annals of Dermatology
- Volume
- 34
- Number
- 6
- Start Page
- 419
- End Page
- 430
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/61920
- DOI
- 10.5021/ad.21.239
- ISSN
- 1013-9087
2005-3894
- Abstract
- Background
Data illustrating the impact of atopic dermatitis (AD) on lives of adults with AD in South Korea are limited.
Objective
To assess the AD disease severity and its impact on quality of life (QoL) in patients with AD from South Korea.
Methods
Patients with AD utilizing the specialist dermatology services of major hospitals in South Korea were assessed for disease severity using Eczema Area and Severity Index (EASI) score, for QoL using Dermatology Life Quality Index (DLQI) (for QoL), and for comorbidities and treatment experience via retrospective review of 12-month medical records. Clinical and sociodemographic characteristics were also measured.
Results
Of the 1,163 patients, 695 (59.8%) were men (mean age [years]±standard deviation: 31.6±12.1). Overall, 52.9% (n=615) patients had moderate-to-severe disease (EASI>7). The QoL of 72.3% (n=840) patients was affected moderately-to-severely (DLQI score: 6~30). Systemic immunosuppressants were used ≥1 over past 12 months in 51.9% (n=603) patients, and the most commonly used were cyclosporines (45.7%, n=531) and systemic corticosteroids (40.5%, n=471). Approximately, 10.8% (n=126) patients consulted or received treatment for AD-related eye problem. Of these, 40% (n=50) patients reported poor, very poor, or completely blind status; approximately, 16.7% patients (n=192) reported having depression or anxiety; and 35.5% (n=410) reported suicidal ideation or suicidal attempt.
Conclusion
A large proportion of patients had moderate-to-severe AD, a compromised QoL, and ocular or mental health comorbidities, indicating a high disease burden despite systemic treatment. These findings highlight the importance of a holistic approach for the evaluation and treatment of patients with AD.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Dermatology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.